<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03184324</url>
  </required_header>
  <id_info>
    <org_study_id>DW_DWP14012002</org_study_id>
    <nct_id>NCT03184324</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease (Phase 2, Therapeutic Exploratory Study)</brief_title>
  <official_title>A Multi-Center, Randomized, Double-Blind, Active-controlled, Phase 2, Therapeutic Exploratory Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy and safety of DWP14012 compared to
      esomeprazole in the treatment of erosive gastroesophageal reflux disease classified as Los
      Angeles(LA) classification grades A to D.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 28, 2017</start_date>
  <completion_date type="Actual">April 18, 2018</completion_date>
  <primary_completion_date type="Actual">April 18, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ratio of subjects who were completely cured of mucosal defects by 8 weeks</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ratio of subjects who were completely cured of mucosal defects by 4 weeks</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">211</enrollment>
  <condition>Erosive Gastroesophageal Reflux Disease</condition>
  <arm_group>
    <arm_group_label>DWP14012 Amg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DWP14012 Amg, tablet, orally, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DWP14012 Bmg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DWP14012 Bmg, tablet, orally, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DWP14012 Cmg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DWP14012 Cmg, tablet, orally, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Esomerpazole 40mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Esomerpazole 40mg, tablet, orally, once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWP14012</intervention_name>
    <description>tablet</description>
    <arm_group_label>DWP14012 Amg</arm_group_label>
    <arm_group_label>DWP14012 Bmg</arm_group_label>
    <arm_group_label>DWP14012 Cmg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole</intervention_name>
    <description>tablet</description>
    <arm_group_label>Esomerpazole 40mg</arm_group_label>
    <other_name>Nexium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWP14012 placebo</intervention_name>
    <description>tablet</description>
    <arm_group_label>DWP14012 Amg</arm_group_label>
    <arm_group_label>DWP14012 Bmg</arm_group_label>
    <arm_group_label>DWP14012 Cmg</arm_group_label>
    <arm_group_label>Esomerpazole 40mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole placebo</intervention_name>
    <description>tablet</description>
    <arm_group_label>DWP14012 Amg</arm_group_label>
    <arm_group_label>DWP14012 Bmg</arm_group_label>
    <arm_group_label>DWP14012 Cmg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults between 20 and 75 years old based on the date of written agreement

          -  Those who have been diagnosed with erosive gastroesophageal reflux disease(EGRD) of LA
             Grade A-D on the upper gastrointestinal endoscopy

          -  Those who experienced symptoms of heartburn or acid reflux within the last 7 days

        Exclusion Criteria:

          -  Those who have undergone gastric acid suppression or gastric, esophageal surgery

          -  Those who with clinically significant liver, kidney, nervous system, respiratory,
             endocrine, hematologic, cardiovascular, urinary system disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hanyang University Medical Center</name>
      <address>
        <city>Sungdogu</city>
        <state>Seoul</state>
        <zip>04763</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>June 8, 2017</study_first_submitted>
  <study_first_submitted_qc>June 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2017</study_first_posted>
  <last_update_submitted>June 20, 2018</last_update_submitted>
  <last_update_submitted_qc>June 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
    <mesh_term>Esophagitis, Peptic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

